vorinostat has been researched along with Cardiac Diseases in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, K | 1 |
| Tang, R | 1 |
| Wang, S | 1 |
| Wang, W | 1 |
| Zhang, K | 1 |
| Li, J | 1 |
| Li, P | 1 |
| Tang, YD | 1 |
| Garber, K | 1 |
2 other studies available for vorinostat and Cardiac Diseases
| Article | Year |
|---|---|
SAHA could inhibit TGF-β1/p38 pathway in MI-induced cardiac fibrosis through DUSP4 overexpression.
Topics: Animals; Fibroblasts; Fibrosis; Heart Diseases; Histone Deacetylase Inhibitors; MAP Kinase Signaling | 2022 |
HDAC inhibitors overcome first hurdle.
Topics: Clinical Trials as Topic; Drug Approval; Heart Diseases; Histone Deacetylase Inhibitors; Humans; Hyd | 2007 |